KILITCH — Kilitch Drugs (India) Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapNeutral

Annual income statement for Kilitch Drugs (India), fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,142	1,396	1,544	1,983	2,355
Cost of Revenue
Gross Profit	392	489	575	689	879
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	1,056	1,256	1,334	1,694	2,025
Operating Profit	86.2	140	210	290	330
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	96.1	120	194	345	387
Provision for Income Taxes
Net Income After Taxes	62.1	82.8	136	249	295
Minority Interest
Net Income Before Extraordinary Items
Net Income	73.7	104	146	267	302
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	73.7	104	146	267	302
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.58	3.55	4.74	8.38	8.91